News Amgen agrees $26bn for Horizon following Sanofi withdrawal In a fresh update, Bloomberg has reported that US biotech Amg
Oncology Servier’s ASCO 2025 Data: Advancing IDH-Mutated Cancer Treat... At ASCO 2025, Servier’s Becky Martin discusses IDH-mutated cancers, including key insights on Tibsovo & Voranigo, and the implications for patients.
